VIVUS, Inc. (NASDAQ:VVUS), Sun Bancorp, Inc. (NASDAQ:SNBC) and H&R Block, Inc. (NYSE:HRB) are three notable analyst upgrades, downgrades and comments made during today’s session.
VIVUS Obesity Medication Looks Attractive
VIVUS, Inc. (VVUS, Free Analysis), a developer of therapeutic products for underserved markets, was initiated at an Outperform with a $20 price target by Wedbush ahead of the opening bell today. The analyst believes that the firm’s Qnexa will help define a new class of obesity medications and views it as one of the most attractive product-driven plays in the mid-cap biotech space.
VIVUS’s experimental weight loss drug, which pairs a stimulant with an epilepsy drug, has shown in studies that it can help patients lose weight and keep it off for a year. Moreover, the drug has even helped some patients lower their blood pressure. Qnexa is up for approval by the FDA in October and has demonstrated impressive results in the eyes of many analysts.